

## JIANBO WEI

Partner

Fangda Partners

+86 10 5769 5719

[jianbo.wei@fangdalaw.com](mailto:jianbo.wei@fangdalaw.com)



### PRACTICE AREAS

MR. JIANBO WEI SPECIALIZES IN OVERSEAS CAPITAL MARKETS, M&A, PRIVATE EQUITY INVESTMENT, FOREIGN DIRECT INVESTMENT AND GENERAL CORPORATE.

### REPRESENTATIVE MATTERS AND CASES

- Represented Kingsoft Cloud Holdings Limited (NASDAQ: KC) in its initial public offering on the NASDAQ
- Represented Qudian Inc. (NYSE: QD) in its initial public offering on the New York Stock Exchange
- Represented Jianpu Technology Inc. (Rong360) (NYSE: JT) in its initial public offering on the New York Stock Exchange
- Represented Cango Inc. (NYSE: CANG) in its initial public offering on the New York Stock Exchange
- Represented the underwriters Morgan Stanley, Credit Suisse, and Citigroup in connection with the initial public offering of Huami Corporation (NYSE: HMI) on the New York Stock Exchange
- Represented the underwriters Citigroup, Deutsche Bank Securities, AMTD, China Merchants Securities (HK), and Tiger Brokers in connection with the initial public offering of UP Fintech Holding Limited (NASDAQ: TIGR) on the NASDAQ
- Represented the underwriters Morgan Stanley and J.P. Morgan in the Kingsoft Corporation Limited (HK: 3888) issuance of HK\$3.1 billion in convertible bonds due 2025
- Represented Warburg Pincus in its strategic investment in Ant Financial

- Represented Warburg Pincus in its strategic investment in Henan Zhongyuan Consumer Finance Co., Ltd
- Represented CITIC PE in its strategic investment in JD Health International Inc
- Represented Junzheng Group in its purchase of a 15.3% stake of Huatai Insurance
- Represented Canada Scotiabank in its strategic investment in the Bank of Xi'an
- Represented Alibaba in its strategic investment in Enlight Media
- Represented Didi Chuxing in its strategic investment in Ren Ren Che
- Represented Primavera Capital in its investment in Souche
- Represented Kuaishou in its Series E financing
- Represented Foshan Deruike Pharmaceuticals Co., Ltd in receiving investment from Hainan Sihuan Pharmaceutical Co., Ltd. of up to RMB 400 million
- Represented Haisco Pharmaceutical Group Co., Ltd, an A-share listed company, in its investment in Israeli medical device enterprises, including MST Medical Surgery Technologies Ltd., Sensible Medical Innovations Ltd., Endospan Ltd., and Newpace Ltd
- Represented Jumei in its investment in Jiedian
- Acted as legal advisor on general corporate affairs for listed companies including Sina, Jianpu (Rong360), Qudian, Jumei, and Cango

## **OTHER INFORMATION**

### **Education**

- Renmin University of China, Master of Laws
- China Foreign Affairs University, Bachelor of Laws
- China Foreign Affairs University, B.A. in English Literature

### **Professional Qualification**

- Admitted to practice in the PRC